التفاصيل البيبلوغرافية
| العنوان: |
Protecting Medicare's Discretion to Say No to Unproven Therapies. |
| المؤلفون: |
Daval CJR; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Bendicksen L; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Kesselheim AS; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. |
| المصدر: |
JAMA [JAMA] 2023 Sep 26; Vol. 330 (12), pp. 1133-1134. |
| نوع المنشور: |
Journal Article |
| اللغة: |
English |
| بيانات الدورية: |
Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE |
| أسماء مطبوعة: |
Original Publication: Chicago : American Medical Association, 1960- |
| مواضيع طبية MeSH: |
Medicare*/economics , Medicare*/legislation & jurisprudence , Therapies, Investigational*/economics, Aged ; Humans ; United States |
| فهرسة مساهمة: |
Local Abstract: [plain-language-summary] In this Viewpoint, Kesselheim and coauthors discuss 2 bills in Congress that would curtail Medicare’s ability to decline, limit, or conditionally cover medical products that lack robust evidence and argue that officials should distinguish between better and worse therapies when determining reimbursement. |
| تواريخ الأحداث: |
Date Created: 20230908 Date Completed: 20230928 Latest Revision: 20230928 |
| رمز التحديث: |
20240628 |
| DOI: |
10.1001/jama.2023.15814 |
| PMID: |
37682556 |
| قاعدة البيانات: |
MEDLINE |
